Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 AlteredExpression disease BEFREE Neuroprotective effects of increasing levels of HSP70 against neuroinflammation in Parkinson's disease model by inhibition of NF-κB and STAT3. 31408661 2019
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 AlteredExpression disease BEFREE We concluded that, FR and Ex improved the motor performance in rotenone-induced PD rodent model which might be due to increased Hsp70 expression and TH density in corpus striatum and combination of both did not offer more protection than FR alone. 30113007 2019
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease BEFREE Here, we report a novel hsp70-independent mechanism by which Hsp90 may also contribute to PD-associated neuropathology. 29471019 2018
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease BEFREE Heat-shock protein 70kDa (Hsp70) is involved in neuroprotection as a molecular chaperone in neurodegenerative disorders such as PD. 29107085 2018
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 AlteredExpression disease BEFREE These findings demonstrated that Hsp70 was an important modulator in astrocytes induced inflammation, and up-regulation of Hsp70 might be a potential regulating approach for neuroinflammation-related neurodegenerative diseases, such as PD. 29183796 2018
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease BEFREE Our findings support the therapeutic relevance of HSP70 induction for the prevention and/or deceleration of PD-like neurodegeneration. 29704482 2018
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease BEFREE Here we investigate the factors controlling the intrinsic ability of human Hsp70 to inhibit the elongation of amyloid fibrils formed by the Parkinson's disease-related protein α-synuclein. 28230968 2017
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease BEFREE HSP70 in particular prevents the aggregation of protein aggregation, such as α-synuclein, providing a degree of protection against PD. 26742515 2017
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease BEFREE Hsp70 regulates α-Synuclein (α-Syn) degeneration in Parkinson's disease (PD), indicating that Hsp70 promotion may be able to prevent or reverse α-Syn-induced toxicity in PD. 28810585 2017
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease BEFREE Thus, Hsp70 is a well‑defined therapeutic target, and Hsp70 promotion is an efficient strategy to prevent or even reverse the α‑synuclein‑induced toxicity in PD. 26135068 2015
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 AlteredExpression disease BEFREE These data confirm that overexpression of Hsp70 holds significant potential as a disease-modulating therapeutic approach for Parkinson's disease, with protective effects against early-onset α-synuclein-induced pathology demonstrated in the AAV-α-synuclein model. 24279716 2014
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 GeneticVariation disease BEFREE Although familial PD is multifactorial in nature, a recent genetic screen involving PD patients identified two mitochondrial Hsp70 variants (P509S and R126W) that are suggested in PD pathogenesis. 22544056 2012
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease RGD Mildronate as a regulator of protein expression in a rat model of Parkinson's disease. 22186119 2011
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 Biomarker disease BEFREE Thus, we demonstrate that systemically applied Tat-Hsp70 effectively prevents neuronal cell death in in vitro and in vivo models of Parkinson's disease. 18182047 2008
CUI: C0030567
Disease: Parkinson Disease
Parkinson Disease
0.300 AlteredExpression disease BEFREE HSP70 mRNA levels in mononuclear blood cells (MBCs) were compared in 14 CJD patients (10 confirmed by histo-pathological study), 12 vascular dementia (VD) patients, 16 patients with Parkinson's disease and dementia (PD) and 14 nondemented control subjects. 11200684 2000